80 research outputs found
Anaphylaxis in Elderly Patients—Data From the European Anaphylaxis Registry
Background: Elicitors and symptoms of anaphylaxis are age dependent. However, little is known about typical features of anaphylaxis in patients aged 65 years or more.Methods: The data from the Network for Online Registration of Anaphylaxis (NORA) considering patients aged ≥65 (elderly) in comparison to data from adults (18–64 years) regarding elicitors, symptoms, comorbidities, and treatment measures were analyzed.Results: We identified 1,123 elderly anaphylactic patients. Insect venoms were the most frequent elicitor in this group (p < 0.001), followed by drugs like analgesics and antibiotics. Food allergens elicited less frequently anaphylaxis (p < 0.001). Skin symptoms occurred less frequently in elderly patients (77%, p < 0.001). The clinical symptoms were more severe in the elderly (51% experiencing grade III/IV reactions), in particular when skin symptoms (p < 0.001) were absent. Most strikingly, a loss of consciousness (33%, p < 0.001) and preexisting cardiovascular comorbidity (59%, p < 0.001) were more prevalent in the elderly. Finally, adrenaline was used in 30% of the elderly (vs. 26% in the comparator group, p < 0.001) and hospitalization was more often required (60 vs. 50%, p < 0.001).Discussion and Conclusion: Anaphylaxis in the elderly is often caused by insect venoms and drugs. These patients suffer more often from cardiovascular symptoms, receive more frequently adrenaline and require more often hospitalization. The data indicate that anaphylaxis in the elderly tends to be more frequently life threatening and patients require intensified medical intervention. The data support the need to recognize anaphylaxis in this patient group, which is prone to be at a higher risk for a fatal outcome
Development of Technology of Arsenic Removal from Acidic Waste Solutions in the Form of Arsenic Trisulfide
During the laboratory tests the conditions of arsenic removal from acidic waste solutions of metallurgical enterprise in the form of arsenic trisulfide were determined. The technology based on the reduction of pentavalent arsenic to trivalent state with sodium pyrosulfite solution and following arsenic trisulfide precipitation from acidic solution after treatment with sodium sulfide solution was proposed. The arsenic removal proceeds with mechanical stirring, dosing the calculated amounts of reagents and collecting emissions of hydrogen sulfide. With such treatment, about 95% of arsenic, which was in the initial solution, passes into the precipitate. An enlarged laboratory experiment was carried out and the precipitate with 42.6% of arsenic and 46.9% of sulfur was obtained. The precipitate yield was ∼25.7 kg (dry weight) out of 1 m3 of the initial arsenic containing solution.
Keywords: arsenic, arsenic trisulfide, acidic waste solutions, sodium sulfide, sodium pyrosulfit
Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry (ISAR)
Funding: ISAR is conducted by Optimum Patient Care Global Ltd, and co-funded by OPC Global Ltd and AstraZeneca.Peer reviewedPublisher PD
Effectiveness of initiating biologics in severe asthma patients with high steroid exposure
Peer reviewedPostprin
Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
Funding: This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. No funding was received by OPRI for its contribution.Peer reviewedPostprin
Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma
Peer reviewedPostprin
Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry
Background: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach. Objective: This study aimed to evaluate the phenotype and risk factors of VIA. Methods: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]). Results: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis. Conclusion: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving β-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA
Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults
Peer reviewe
Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy
Peer reviewedPostprin
Association between T2-related co-morbidities and effectiveness of biologics in severe asthma
Acknowledgments The authors thank Mr. Joash Tan (BSc, Hons), of the Observational and Pragmatic Research Institute (OPRI), and Ms Andrea Lim (BSc, Hons) of the Observational Pragmatic Research Institute (OPRI) for their editorial and formatting assistance that supported the development of this publication. Funding statement: This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. AstraZeneca UK LimitedPeer reviewe
- …